US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines
{{output}}
The US (US) Food and Drug Administration (FDA)-accelerated approval pathway facilitates early access to oncology drugs based on surrogate endpoints, with required confirmatory post-marketing trials. However, regulatory decisions vary globally, with some drugs ... ...
